Back to Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 4

Antidiabetic effect of glucosaminic acid-cobalt (II) chelate in streptozotocin-induced diabetes in mice

Authors Tahirou T, Shui XW, Cheng Q, Xin Tian

Published 18 April 2011 Volume 2011:4 Pages 137—140

DOI https://doi.org/10.2147/DMSO.S18025

Review by Single-blind

Peer reviewer comments 2


Tahirou Talba1, Xia Wen Shui1, Qinyuan Cheng1,2, Xin Tian2
1Key Laboratory of Food Processing Technology, 2School of Medicine and Pharmaceutics, Jiangnan University, Wuxi, Jiangsu, People's Republic of China

Background: The purpose of this study was to assess the in vivo ability of glucosaminic acid-cobalt (II) chelate to reduce glycemia.
Methods: Different concentrations of chelate solution were administrated to mice with diabetes induced by streptozotocin. Daily oral administration of chelate solution 0.4 mL at various concentrations (0.32–0.4 g/mL) led to reduction in water intake by the diabetic mice after 5 days of treatment, with a subsequent reduction in glucose levels observed 2 weeks later. Daily food intake was related to both chelate concentration as well as glycemia reduction. The food intake of mice treated with glucosaminic acid-cobalt (II) chelate solution was 1.5-fold that of untreated mice.

Keywords: glucosaminic acid, cobalt, chelate, streptozotocin, glycemia reduction

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]